Integrilin Dosage
Generic name: Eptifibatide 0.75mg in 1mL
Dosage form: injection, solution
Drug class: Glycoprotein platelet inhibitors
Medically reviewed by Drugs.com. Last updated on Oct 23, 2023.
Before infusion of INTEGRILIN, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured.
The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT.
Dosage in Acute Coronary Syndrome (ACS)
Indication | Normal Renal Function | Creatinine Clearance less than 50 mL/min |
---|---|---|
Patients with ACS | 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min | 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min |
|
INTEGRILIN should be given concomitantly with heparin dosed to achieve the following parameters:
- During Medical Management: Target aPTT 50 to 70 seconds
- If weight greater than or equal to 70 kg, 5000-unit bolus followed by infusion of 1000 units/h.
- If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h.
- During PCI: Target ACT 200 to 300 seconds
- If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds.
- Heparin infusion after the PCI is discouraged.
Dosage in Percutaneous Coronary Intervention (PCI)
Indication | Normal Renal Function | Creatinine Clearance less than 50 mL/min |
---|---|---|
Patients with PCI | 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) | 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) |
|
- INTEGRILIN should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60-units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI.
- Additional boluses during PCI to maintain ACT within target.
- Heparin infusion after the PCI is strongly discouraged.
Patients requiring thrombolytic therapy should discontinue INTEGRILIN.
Important Administration Instructions
- Inspect INTEGRILIN for particulate matter and discoloration prior to administration, whenever solution and container permit.
- May administer INTEGRILIN in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer INTEGRILIN through the same intravenous line as furosemide.
- May administer INTEGRILIN in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride.
- Withdraw the bolus dose(s) of INTEGRILIN from the 10-mL vial into a syringe. Administer the bolus dose(s) by IV push.
- Immediately following the bolus dose administration, initiate a continuous infusion of INTEGRILIN. When using an intravenous infusion pump, administer INTEGRILIN undiluted directly from the 100-mL vial. Spike the 100-mL vial with a vented infusion set. Center the spike within the circle on the stopper top.
- Discard any unused portion left in the vial.
Administer INTEGRILIN by volume according to patient weight (see Table 1).
Patient Weight | 180-mcg/kg Bolus Volume |
2-mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) |
1-mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) |
|||
---|---|---|---|---|---|---|
(kg) | (lb) | (from 2-mg/mL vial) | (from 2-mg/mL 100-mL vial) | (from 0.75-mg/mL 100-mL vial) | (from 2-mg/mL 100-mL vial) | (from 0.75-mg/mL 100-mL vial) |
37-41 | 81-91 | 3.4 mL | 2 mL/h | 6 mL/h | 1 mL/h | 3 mL/h |
42-46 | 92-102 | 4 mL | 2.5 mL/h | 7 mL/h | 1.3 mL/h | 3.5 mL/h |
47-53 | 103-117 | 4.5 mL | 3 mL/h | 8 mL/h | 1.5 mL/h | 4 mL/h |
54-59 | 118-130 | 5 mL | 3.5 mL/h | 9 mL/h | 1.8 mL/h | 4.5 mL/h |
60-65 | 131-143 | 5.6 mL | 3.8 mL/h | 10 mL/h | 1.9 mL/h | 5 mL/h |
66-71 | 144-157 | 6.2 mL | 4 mL/h | 11 mL/h | 2 mL/h | 5.5 mL/h |
72-78 | 158-172 | 6.8 mL | 4.5 mL/h | 12 mL/h | 2.3 mL/h | 6 mL/h |
79-84 | 173-185 | 7.3 mL | 5 mL/h | 13 mL/h | 2.5 mL/h | 6.5 mL/h |
85-90 | 186-198 | 7.9 mL | 5.3 mL/h | 14 mL/h | 2.7 mL/h | 7 mL/h |
91-96 | 199-212 | 8.5 mL | 5.6 mL/h | 15 mL/h | 2.8 mL/h | 7.5 mL/h |
97-103 | 213-227 | 9 mL | 6 mL/h | 16 mL/h | 3.0 mL/h | 8 mL/h |
104-109 | 228-240 | 9.5 mL | 6.4 mL/h | 17 mL/h | 3.2 mL/h | 8.5 mL/h |
110-115 | 241-253 | 10.2 mL | 6.8 mL/h | 18 mL/h | 3.4 mL/h | 9 mL/h |
116-121 | 254-267 | 10.7 mL | 7 mL/h | 19 mL/h | 3.5 mL/h | 9.5 mL/h |
>121 | >267 | 11.3 mL | 7.5 mL/h | 20 mL/h | 3.7 mL/h | 10 mL/h |
More about Integrilin (eptifibatide)
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- Drug class: glycoprotein platelet inhibitors
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.